Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REAL8: Weekly somapacitan versus daily Norditropin in pediatric short stature disorders
MOH_2022-07-25_011827Phase 3Active, not recruiting
- Sponsor
- Novo Nordisk
- Start
- Jun 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in Short stature in children born small for gestational age, Turner syndrome (TS), Noonan syndrome and 1 more comparing Somapacitan once weekly with Norditropin once daily then somapacitan once weekly (2 arms). Started Jun 2022; status: active, not recruiting.
02
Drugs
somapacitansomatropin
03
Conditions
Short stature in children born small for gestational ageTurner syndrome (TS)Noonan syndromeIdiopathic Short Stature (ISS)
Beyond the preview
Go deeper on MOH_2022-07-25_011827.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-07-25_011827.